JOUNCE THERAPEUTICS (JNCE) Covered Calls

You can sell covered calls on JOUNCE THERAPEUTICS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for JNCE (prices last updated Fri 4:16 PM ET):

JOUNCE THERAPEUTICS (JNCE) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
4.40 -0.15 3.52 5.00 334K - 0.1B
Covered Calls For JOUNCE THERAPEUTICS (JNCE)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Dec 21 5 0.15 4.85 3.1% 31.4%
Mar 15 5 0.40 4.60 8.7% 26.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.